DaVita Inc. (DVA) Return on Equity (ROE): -114.70%
Is DaVita Inc.’s return on equity (ROE) high or low?
DaVita Inc.'s return on equity (ROE) of -114.70% is 170% below its 5-year average of 164.66%, near the low end of its 5-year range (-114.70%–773.06%).
As of Monday, June 15, 2026. 134.84% below its 12-month average of 329.18%.
DVA Return on Equity (ROE) Chart
DVA Average Return on Equity (ROE) Chart
DVA Current vs Average Return on Equity (ROE) Chart
DVA Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
-114.70%
RETURN ON EQUITY (ROE) AVG TTM
329.18%
RETURN ON EQUITY (ROE) AVG 3Y
200.63%
RETURN ON EQUITY (ROE) AVG 5Y
164.66%
RETURN ON EQUITY (ROE) AVG 10Y
97.17%
RETURN ON EQUITY (ROE) AVG 15Y
28.18%
RETURN ON EQUITY (ROE) AVG 20Y
23.46%
CURRENT VS TTM AVG
-134.84%
CURRENT VS 3Y AVG
-157.17%
CURRENT VS 5Y AVG
-169.66%
CURRENT VS 10Y AVG
-218.04%
CURRENT VS 15Y AVG
-507.00%
CURRENT VS 20Y AVG
-588.92%
DVA Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DaVita Inc. (DVA) | $13.40B | -114.70% | 329.18% | 200.63% | 164.66% |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 2.86% | 4.70% | 4.67% | 11.22% |
| Solventum Corporation (SOLV)vs › | $13.66B | 28.82% | 23.51% | 17.50% | 13.68% |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 10.36% | 10.54% | 10.84% | 19.93% |
| Baxter International Inc. (BAX)vs › | $10.77B | -18.17% | -12.46% | -8.76% | -1.37% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -87.68% | -49.03% | -18.16% | -9.00% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | -6.28% | -2.13% | 6.32% | 9.65% |
| Tempus AI, Inc. (TEM)vs › | $8.35B | -72.74% | -651.33% | -315.37% | -198.08% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | 2.46% | -8.94% | -15.72% | 1.14% |
Return Analysis
ROE
-114.7%
ROA
4.5%
DaVita Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DaVita Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for DaVita Inc. (DVA)?
- The return on equity (ROE) for DVA stock is -114.70%.
- Is DaVita Inc.'s return on equity (ROE) high or low?
- DaVita Inc.'s return on equity (ROE) of -114.70% is 170% below its 5-year average of 164.66%, near the low end of its 5-year range (-114.70%–773.06%).
- What is the TTM average return on equity (ROE) for DaVita Inc. (DVA)?
- The TTM average return on equity (ROE) for DVA stock is 329.18%.
- What is the 3Y average return on equity (ROE) for DaVita Inc. (DVA)?
- The 3Y average return on equity (ROE) for DVA stock is 200.63%.
- What is the 5Y average return on equity (ROE) for DaVita Inc. (DVA)?
- The 5Y average return on equity (ROE) for DVA stock is 164.66%.
- What is the 10Y average return on equity (ROE) for DaVita Inc. (DVA)?
- The 10Y average return on equity (ROE) for DVA stock is 97.17%.
- What is the 15Y average return on equity (ROE) for DaVita Inc. (DVA)?
- The 15Y average return on equity (ROE) for DVA stock is 28.18%.
- What is the 20Y average return on equity (ROE) for DaVita Inc. (DVA)?
- The 20Y average return on equity (ROE) for DVA stock is 23.46%.
DaVita Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -114.70% |
| 2024-12-31 | 773.06% |
| 2023-12-31 | 65.48% |
| 2022-12-31 | 78.67% |
| 2021-12-31 | 129.51% |
| 2020-12-31 | 55.92% |
| 2019-12-31 | 38.01% |
| 2018-12-31 | 4.30% |
| 2017-12-31 | 14.15% |
| 2016-12-31 | 18.93% |
| 2015-12-31 | 5.54% |
| 2014-12-31 | 13.99% |
| 2013-12-31 | 14.29% |
| 2012-12-31 | 14.24% |
| 2011-12-31 | 22.33% |
| 2010-12-31 | 20.51% |
| 2009-12-31 | 19.80% |
| 2008-12-31 | 19.16% |
| 2007-12-31 | 22.04% |
| 2006-12-31 | 23.25% |
| 2005-12-31 | 26.88% |
| 2004-12-31 | 42.49% |
| 2003-12-31 | 57.28% |
| 2002-12-31 | 223.91% |
| 2001-12-31 | 27.26% |
| 2000-12-31 | 3.86% |
| 1999-12-31 | -45.11% |
| 1998-12-31 | -1.95% |
| 1997-12-31 | 16.62% |
| 1996-12-31 | 11.56% |
Related Metrics
About DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Javier J. Rodriguez